Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-001 (ACM Biolabs)
- Development stage
- Unknown
- Lead developer
- ACM Biolabs
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intranasal
01
Overview
**ACM-001** is an investigational, adjuvanted SARS-CoV-2 booster vaccine developed by ACM Biolabs for prevention of COVID-19. The vaccine contains a SARS-CoV-2 beta-variant spike-protein antigen together with the CpG 7909 immunostimulatory adjuvant, formulated using ACM Biolabs' polymer-based Tunable Platform delivery technology. It was evaluated as a single booster dose by intramuscular injection and intranasal administration in a completed Phase 1 study in previously vaccinated healthy adults. ([acmbiolabs.com](https://acmbiolabs.com/acm-biolabs-announces-positive-topline-results-from-a-phase-i-trial-of-sars-cov-2-booster-vaccine-acm-001/))
- Other names
- ACM-SARS-CoV-2-beta ACM-CpG vaccine candidateACM-SARS-CoV2-beta ACM-CpG vaccine candidateACM-SARS-CoV 2-beta ACM-CpG vaccine candidate
02
Targets
SARS-CoV-2 spikeTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on ACM-001 (ACM Biolabs).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-001 (ACM Biolabs).